POZ Community Forums

Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: Jim Allen on May 20, 2020, 10:06:14 pm

Title: FDA Approves First New Kaposi Sarcoma Treatment in Over 20 Years
Post by: Jim Allen on May 20, 2020, 10:06:14 pm

Always good to see additional treatment options being added.

POZ.Com full write-up https://www.poz.com/article/fda-approves-first-new-kaposi-sarcoma-treatment-20-years

In short:
Pomalyst is an immunomodulatory drug related to thalidomide. It boosts immune function by promoting the activity of T-cells and natural killer cells. In addition, it inhibits the growth of cancer cells and blocks development of blood vessels that feed tumors. It was previously approved for multiple myeloma, a blood cancer that involves white blood cells in the bone marrow.

The new approval was supported by findings from Study 12-C-0047, a Phase I/II clinical trial conducted by the National Cancer Institute. This open-label study included 18 HIV-positive and 10 HIV-negative people with KS. Most had advanced disease, but those with symptomatic KS affecting their lungs or internal organs were excluded, as were those with a history of blood clots.